thiophenes has been researched along with Parkinson Disease, Secondary in 13 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (15.38) | 18.7374 |
| 1990's | 7 (53.85) | 18.2507 |
| 2000's | 1 (7.69) | 29.6817 |
| 2010's | 2 (15.38) | 24.3611 |
| 2020's | 1 (7.69) | 2.80 |
| Authors | Studies |
|---|---|
| Alhakamy, NA; Anwer, MK; Bhattamisra, SK; Choudhury, H; Lim, WM; Md, S; Radhakrishnan, AK; Safian, NH; Shahzad, N; Shak, AT; Xi, LW | 1 |
| Zarola, F | 1 |
| Anticoli, S; Dalmaso, SG; Marchitto, N; Pannozzi, A; Raimondi, G; Sindona, F | 1 |
| Bezard, E; Chan, P; Crossman, AR; Guan, L; Guigoni, C; Hill, M; Li, Q; Ravenscroft, P; Scheller, D; Wu, T; Zhang, R | 1 |
| Bankiewicz, KS; Belluzzi, JD; Domino, EF; May, JM; McAfee, DA | 1 |
| Asin, KE; Bianchi, B; Britton, DR; Didomenico, S; Hodges, L; Hong, Y; Jenner, P; Lin, CW; Mahan, L; Michaelides, M; Mikusa, J; Miller, T; Nikkel, A; Shiosaki, K; Smith, L; Stashko, M; Williams, M; Witte, D | 1 |
| Asin, KE; Bayburt, EK; Britton, DR; DiDomenico, S; Hong, Y; Lin, CW; Michaelides, MR; Shiosaki, K | 1 |
| Domino, EF | 1 |
| Bédard, PJ; Britton, DR; Grondin, R; Shiosaki, K | 1 |
| Domino, EF; Ni, L | 1 |
| Domino, EF; Ni, L; Zhang, H | 1 |
| Chong, PN; Horn, AS; Jenner, P; Löschmann, PA; Marsden, CD; Nomoto, M; Tepper, PG | 1 |
| Ishida, R; Kojima, M; Kowa, Y; Nose, T; Shintomi, K | 1 |
13 other study(ies) available for thiophenes and Parkinson Disease, Secondary
| Article | Year |
|---|---|
Nose to brain delivery of rotigotine loaded chitosan nanoparticles in human SH-SY5Y neuroblastoma cells and animal model of Parkinson's disease.
Topics: Administration, Intranasal; alpha-Synuclein; Animals; Blood-Brain Barrier; Cell Line, Tumor; Chitosan; Disease Models, Animal; Dopamine Agonists; Drug Carriers; Female; Haloperidol; Humans; Male; Nanoparticles; Neurons; Oxidopamine; Parkinson Disease, Secondary; Particle Size; Rats; Tetrahydronaphthalenes; Thiophenes; Toxicity Tests, Acute | 2020 |
Vascular Parkinsonism sensitive to Rotigotine therapy is found in aged patients: a clinical case description.
Topics: Aged, 80 and over; Cerebral Infarction; Dopamine Agonists; Female; Humans; Magnetic Resonance Imaging; Necrosis; Parkinson Disease, Secondary; Tetrahydronaphthalenes; Thiophenes; Transdermal Patch; White Matter | 2018 |
Safety and efficacy of Rotigotine in hospedalized patients with Vascular Parkinsonism aged 75 and older: effects on movement, praxis capacities, time-space orientation, quality of life and adherence to medical therapy.
Topics: Administration, Cutaneous; Aged; Aged, 80 and over; Brain Ischemia; Cognition; Dopamine Agonists; Female; Geriatric Assessment; Hospitalization; Humans; Inpatients; Male; Movement; Parkinson Disease, Secondary; Patient Safety; Prospective Studies; Quality of Life; Risk Assessment; Sampling Studies; Severity of Illness Index; Stroke; Tetrahydronaphthalenes; Thiophenes; Time Perception; Transdermal Patch; Treatment Outcome | 2019 |
Rotigotine treatment partially protects from MPTP toxicity in a progressive macaque model of Parkinson's disease.
Topics: Animals; Autoradiography; Dopamine Agonists; Dopamine Plasma Membrane Transport Proteins; Female; Immunohistochemistry; Macaca fascicularis; MPTP Poisoning; Neostriatum; Organotechnetium Compounds; Parkinson Disease, Secondary; Radiopharmaceuticals; Tetrahydronaphthalenes; Thiophenes; Tomography, Emission-Computed, Single-Photon; Tropanes; Tyrosine 3-Monooxygenase | 2007 |
N-0923, a selective dopamine D2 receptor agonist, is efficacious in rat and monkey models of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Bromocriptine; Disease Models, Animal; Dominance, Cerebral; Dopamine Agents; Female; Injections, Intramuscular; Macaca nemestrina; Male; Oxazines; Oxidopamine; Parkinson Disease, Secondary; Prolactin; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D2; Stereotyped Behavior; Substantia Nigra; Tetrahydronaphthalenes; Thiophenes | 1994 |
ABT-431: the diacetyl prodrug of A-86929, a potent and selective dopamine D1 receptor agonist: in vitro characterization and effects in animal models of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Behavior, Animal; Callithrix; CHO Cells; Corpus Striatum; Cricetinae; Disease Models, Animal; Dopamine Agonists; Dose-Response Relationship, Drug; Female; Fishes; Humans; Kinetics; Male; Mice; Parkinson Disease, Secondary; Prodrugs; Pyridines; Quinolones; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D1; Tetrahydronaphthalenes; Thiophenes | 1996 |
Substituted hexahydrobenzo[f]thieno[c]quinolines as dopamine D1-selective agonists: synthesis and biological evaluation in vitro and in vivo.
Topics: Adenylyl Cyclases; Animals; Benzazepines; Binding, Competitive; Cell Membrane; Corpus Striatum; Dopamine Agonists; Dopamine Antagonists; Fishes; Mice; Molecular Structure; Oxidopamine; Parkinson Disease, Secondary; Quinolones; Receptors, Dopamine; Retina; Stereoisomerism; Structure-Activity Relationship; Thiophenes; Tritium; Yohimbine | 1997 |
Selective full dopamine D1-like (SKF-82958) and D2-like (N-0923) agonist combination in the MPTP monkey model of hemiparkinsonism.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Benzazepines; Disease Models, Animal; Dopamine Agonists; Drug Evaluation, Preclinical; Drug Interactions; Female; Macaca nemestrina; Parkinson Disease, Secondary; Receptors, Dopamine D1; Receptors, Dopamine D2; Tetrahydronaphthalenes; Thiophenes | 1997 |
Potential therapeutic use of the selective dopamine D1 receptor agonist, A-86929: an acute study in parkinsonian levodopa-primed monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Dopamine Agents; Dopamine Agonists; Dyskinesia, Drug-Induced; Female; Levodopa; Macaca fascicularis; Motor Activity; Parkinson Disease, Secondary; Quinolones; Quinpirole; Receptors, Dopamine D1; Thiophenes | 1997 |
Trihexyphenidyl interactions with the dopamine D1-selective receptor agonist SKF-82958 and the D2-selective receptor agonist N-0923 in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced hemiparkinsonian monkeys.
Topics: Animals; Antiparkinson Agents; Benzazepines; Dopamine Agonists; Dose-Response Relationship, Drug; Drug Synergism; Female; Macaca nemestrina; MPTP Poisoning; Parkinson Disease, Secondary; Receptors, Dopamine D1; Receptors, Dopamine D2; Tetrahydronaphthalenes; Thiophenes; Trihexyphenidyl | 1998 |
Nicotine alone and in combination with L-DOPA methyl ester or the D(2) agonist N-0923 in MPTP-induced chronic hemiparkinsonian monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Dopamine Agonists; Drug Interactions; Female; Levodopa; Macaca nemestrina; Motor Activity; Nicotine; Parkinson Disease, Secondary; Receptors, Dopamine D2; Rotation; Tetrahydronaphthalenes; Thiophenes | 1999 |
Stereoselective reversal of MPTP-induced parkinsonism in the marmoset after dermal application of N-0437.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Administration, Topical; Animals; Callitrichinae; Dopamine Agents; Female; Injections, Intraperitoneal; Injections, Subcutaneous; Male; Motor Activity; Naphthalenes; Parkinson Disease, Secondary; Stereoisomerism; Tetrahydronaphthalenes; Thiophenes; Time Factors | 1989 |
[Pharmacological properties of 6,6,9-trimethyl-9-azabicyclo (3,3,1)non-3 beta-yl-alpha, alpha-di(2-thienyl) glycolate hydrochloride monohydrate (PG-501), a new anti-parkinsonian agent].
Topics: Acetylcholine; Analgesics; Anesthetics, Local; Animals; Anticonvulsants; Barbiturates; Behavior, Animal; Blood Pressure; Body Temperature; Cats; Depression, Chemical; Drug Synergism; Electroencephalography; Gastrointestinal Motility; Glycolates; Guinea Pigs; Haloperidol; Haplorhini; Heterocyclic Compounds; In Vitro Techniques; Male; Mice; Neuromuscular Junction; Nictitating Membrane; Parasympatholytics; Parkinson Disease, Secondary; Physostigmine; Pupil; Rabbits; Reserpine; Respiration; Salivation; Thiophenes; Tremor; Tremorine | 1971 |